MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies

MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies

Mesenchymal–epithelial transition factor (MET) amplification has been suggested either as a de novo or acquired mechanism of resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy. However, even if MET amplification has been widely described in the preclinical setting, only a few cl...

Full description

Bibliographic Details
Main Authors: Patricia Martin Romano, Eduardo Castanon, Antoine Hollebecque, Ludovic Lacroix, Nathalie Auger, Eric Angevin, Lambros Tselikas, Sami Ammari, Jean-Charles Soria, Christophe Massard
Format: Article
Language:English
Published: Innovative Healthcare Institute 2019-06-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
anti-epidermal growth factor receptor
cholangiocarcinoma
gene amplification
mesenchymal–epithelial transition factor
resistance
Online Access:https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_7_19

Internet

https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_7_19

Similar Items